There is an exciting opportunity to work at Imperial College Healthcare NHS Trust (Clinical Oncology services) in support of the further development of stereotactic radiotherapy services, focusing on service improvement, education and clinical research, depending on your clinical training needs.
This is a fixed term 12 month contract (with potential to extend), with on-call supplement opportunity if required (not essential/required in post). It is ideally suited to a FRCR qualified trainee, wanting to expand and develop their CV prior to consultant post application. Non-UK trained applicants with current GMC registration, significant relevant radiation oncology training/clinical experience are also invited to apply, subject to initial discussion with the Clinical Director to ensure that role would fit with PP (ex. CESR) training needs. The post allows considerable flexibility for the doctors to choose their area of research or education, to develop their CVs or clinical experience
At Imperial College Healthcare you can achieve extraordinary things with extraordinary people, working with leading clinicians pushing boundaries in patient care.
Become part of a vibrant team living our values - expert, kind, collaborative and aspirational. You’ll get an experience like no other and will fast forward your career.
Benefits include career development, flexible working and wellbeing, staff recognition scheme. Make use of optional benefits including Cycle to Work, car lease schemes, season ticket loan or membership options for onsite leisure facilities.
We are committed to equal opportunities and improving the working lives of our staff and will consider applications to work flexibly, part time or job share. Please talk to us at interview.
The successful candidate will support the lung and wider stereotactic team for service delivery, and will work with other relevant clinical teams to help progress developments in our expanding SRS and SABR services at ICHT. There will be an opportunities to receiving training in a variety of tumour areas as per educational needs as required. ICHT has been delivering SABR for lung cancer since 2020 and is rapidly expanding to treat oligometastatic disease in line with NHS guidance
